(Q36120809)

12 August 2017

1 reference

title

Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor (English)

1 reference

12 August 2017

1 reference

Bernard Bannwarth

1

1 reference

12 August 2017

Francis Berenbaum

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

published in

1 reference

12 August 2017

volume

14

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

521-533

1 reference

Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Worsening heart failure associated with COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Arthritis medicines and cardiovascular events--"house of coxibs".

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Do selective cyclo-oxygenase-2 inhibitors have a future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

A coxib a day won't keep the doctor away

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Assessment of lumiracoxib bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Pharmacokinetics of lumiracoxib in plasma and synovial fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Concomitant administration of lumiracoxib and a triphasic oral contraceptive does not affect contraceptive activity or pharmacokinetic profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Efficacy of lumiracoxib in osteoarthritis: a review of nine studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

The role of non-steroidal anti-inflammatory drugs in acute liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis. Support for the concept of “responders” and “nonresponders”

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.521

10.1517/13543784.14.4.521

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference